Recombinant Human 5-hydroxytryptamine receptor 1F (HTR1F)

What is HTR1F and how is it distributed in the brain?

HTR1F is a G protein-coupled receptor that belongs to the 5-HT1 subfamily of serotonin receptors. Transcriptomic analyses reveal that HTR1F is among the most abundantly transcribed serotonin receptors, alongside HTR2C, in the mouse brain . The receptor is widely distributed throughout the brain with expression patterns that vary by region and cell type.

Single-cell RNA sequencing data indicates that HTR1F expression is highest in neuronal populations, particularly in excitatory neurons . HTR1F rarely acts alone at the cellular level - approximately 60.84% of cells that express any serotonin receptor exhibit RNA of at least two different receptor subtypes, with HTR1F frequently co-expressed with other serotonin receptors . This co-expression pattern has significant implications for understanding serotonergic signaling complexity.

How does HTR1F differ from other 5-HT receptor subtypes?

Key differences include:

• HTR1F demonstrates higher affinity for certain compounds, including sumatriptan and 5-N-butyryloxy-N,N-dimethyltryptamine (BODMT), which shows >60-fold selectivity for HTR1F versus HTR1E .

• While both receptors require the 5-hydroxyl group of serotonin for optimal binding, the impact of its removal differs between the subtypes, with HTR1F showing more significant affinity reduction.

• HTR1F exhibits unique genetic regulatory mechanisms that influence its expression in specific neuronal populations .

What are the key binding requirements for HTR1F ligands?

Structure-activity relationship studies have revealed several critical features that determine binding affinity at the HTR1F receptor:

• The 5-hydroxyl group is essential for high-affinity binding. Replacing this group with hydrogen (as in tryptamine) reduces binding affinity by approximately 70-fold compared to serotonin .

• The indolic nitrogen atom plays an important role in receptor recognition.

• The nature of the terminal amine significantly impacts binding affinity. For example, N,N-dimethylation of serotonin produces compounds with nanomolar affinity (Ki = 4 nM) .

• Modifications at the 3-position of the indole ring can be tolerated and potentially exploited for selective ligand design.

Table 1: Key binding affinities of representative compounds at HTR1F receptor

How can selectivity between HTR1F and HTR1E be achieved in ligand design?

• Focus on 5-position modifications: The discovery that 5-N-butyryloxy-N,N-dimethyltryptamine (BODMT) displays over 60-fold selectivity for HTR1F versus HTR1E suggests that bulky substitutions at the 5-position may provide a path to selective ligands .

• Exploit differences in the binding pocket: Though the receptors share high homology, subtle differences in their orthosteric binding sites can be leveraged. Molecular modeling studies indicate that the HTR1F binding pocket may accommodate certain bulky substituents better than HTR1E.

• Consider allosteric modulation: Given the difficulty in achieving selectivity through orthosteric binding, researchers should explore allosteric modulators that might provide greater subtype selectivity.

• Develop radio-labeled selective ligands: For research applications, developing highly selective radioligands would significantly advance the understanding of HTR1F distribution and function.

What are the optimal approaches for studying HTR1F expression in tissue samples?

Several complementary methods can be employed to study HTR1F expression effectively:

• Single-cell RNA sequencing (scRNA-seq): This approach has proven valuable for mapping HTR1F expression across different cell types. Studies have revealed that HTR1F is predominantly expressed in neuronal populations, particularly excitatory neurons . The technique allows for co-expression analysis with other receptors and genes.

• MERFISH (Multiplexed Error-Robust Fluorescence In Situ Hybridization): This technique provides spatial context to expression data and has been successfully used to validate scRNA-seq findings for various serotonin receptors .

• Quantitative PCR: For targeted analysis of HTR1F expression across different tissues or experimental conditions, qPCR remains a valuable approach.

• Expression quantitative trait loci (eQTL) analysis: This method has been used to identify genetic variants that influence HTR1F expression levels. For example, the variant rs1818163 has been associated with HTR1F expression regulation in neurons (beta = -0.030, P = 1.2e-4) .

How can recombinant HTR1F be optimally expressed for functional studies?

For functional characterization of HTR1F, researchers should consider:

How does HTR1F co-expression with other serotonin receptors affect experimental design?

The high degree of co-expression between HTR1F and other serotonin receptors presents significant experimental considerations:

Transcriptomic data reveals that 60.84% of cells expressing any serotonin receptor contain mRNA for at least two different receptor subtypes, and only 25.78% express a single receptor subtype . Remarkably, about 7.4% of serotonin receptor-expressing cells contain mRNA for five or more receptor subtypes .

This co-expression pattern necessitates careful experimental design:

• Pharmacological isolation: When studying HTR1F function, researchers should use cocktails of antagonists to block other serotonin receptors or employ knockdown/knockout approaches to isolate HTR1F-specific effects.

• Heteromerization potential: Consider the possibility of receptor heteromerization affecting signaling properties. This may require bioluminescence resonance energy transfer (BRET) or fluorescence resonance energy transfer (FRET) studies to assess receptor-receptor interactions.

• Cell type-specific targeting: When possible, target studies to neuronal populations with high HTR1F expression relative to other serotonin receptors. Single-cell transcriptomic data can guide these selections .

• Compensation mechanisms: In knockout/knockdown studies, consider that other serotonin receptors may compensate for HTR1F loss, potentially confounding results.

What is the significance of HTR1F in sleep regulation and sleep disorders?

Genome-wide association studies have identified a significant association between HTR1F genetic variants and sleep apnea, particularly in non-obese individuals . This reveals a potentially important role for serotonergic signaling through HTR1F in sleep regulation.

Key findings include:

• The variant rs1818163 at the HTR1F locus shows association with obstructive sleep apnea in individuals with BMI under 30 (20,413 cases and 443,463 controls) .

• Fine-mapping analysis produced a credible set of 82 variants, with rs1818163 as the lead variant, suggesting regulatory influence on HTR1F expression .

• Objectively measured sleep-activity data showed association with number of awakenings during night (P = 5.6e-8) .

• eQTL data supports a regulatory role of rs1818163 on HTR1F expression specifically in neurons (beta = -0.030, P = 1.2e-4) .

These findings suggest HTR1F may influence sleep apnea liability through neuronal mechanisms rather than through obesity-related pathways, opening new research directions for both sleep disorders and HTR1F function.

What approaches can be used to study HTR1F's role in neuronal function?

Investigating HTR1F's role in neuronal function requires multifaceted approaches:

• Electrophysiological techniques:

  • Patch-clamp recordings in brain slices following application of selective HTR1F agonists

  • Multi-electrode arrays to examine network-level effects of HTR1F modulation

• Optogenetic and chemogenetic approaches:

  • Express opsins in HTR1F-expressing neurons using Cre-dependent strategies

  • Combine with in vivo calcium imaging to monitor activity patterns

• Behavioral models:

  • Conditional knockout models restricted to specific neuronal populations

  • Pharmacological studies using selective HTR1F agonists/antagonists

• Imaging approaches:

  • PET imaging with selective radioligands to study receptor occupancy

  • Functional MRI to assess brain-wide effects of HTR1F modulation

How can genetic variants of HTR1F be studied for functional consequences?

To investigate the functional impact of HTR1F genetic variants:

• CRISPR-Cas9 genome editing:

  • Introduce specific variants (e.g., rs1818163) in cellular models

  • Create animal models carrying human variants of interest

• Reporter gene assays:

  • Clone promoter/enhancer regions containing variants of interest

  • Assess their impact on transcriptional activity

• eQTL analysis in relevant tissues:

  • Analyze expression data from brain tissue in relation to genotype

  • Focus on neuronal populations where HTR1F is highly expressed

• Functional genomics approaches:

  • Chromosome conformation capture (3C, Hi-C) to assess long-range interactions

  • ATAC-seq to evaluate chromatin accessibility around variants

  • ChIP-seq to identify transcription factor binding affected by variants

What are the therapeutic implications of selective HTR1F modulation?

The unique properties of HTR1F make it an intriguing target for several therapeutic areas:

• Migraine treatment: Several triptans with affinity for HTR1F receptors are used clinically for migraine, suggesting potential for more selective HTR1F agonists in this indication .

• Sleep disorders: The genetic association between HTR1F variants and sleep apnea suggests potential therapeutic applications in sleep medicine, particularly for non-obese patients with sleep apnea .

• Neuropsychiatric conditions: Given the expression pattern in neuronal populations, HTR1F modulation might have applications in anxiety, depression, or other conditions where serotonergic signaling plays a role.

A methodological challenge remains in developing compounds with sufficient selectivity for HTR1F over other serotonin receptors. The identification of 5-N-butyryloxy-N,N-dimethyltryptamine (BODMT) with >60-fold selectivity for HTR1F versus HTR1E represents an important step forward in this direction .

How can HTR1F-focused research advance precision medicine approaches?

HTR1F research has several implications for precision medicine:

• Genetic stratification: The association of HTR1F variants with sleep apnea in non-obese individuals suggests potential for genetically-guided treatment approaches. Patients could be stratified based on HTR1F variants for targeted therapies .

• Biomarker development:

  • Develop imaging ligands for HTR1F to assess receptor density in patients

  • Investigate whether HTR1F expression levels in accessible tissues correlate with brain expression

  • Determine if circulating markers reflect HTR1F activity

• Personalized treatment selection:

  • Identify whether HTR1F genetic variants predict response to serotonergic medications

  • Develop pharmacogenomic approaches to guide treatment selection

• Drug development implications:

  • Target development of HTR1F-selective compounds for specific patient subpopulations

  • Consider HTR1F polymorphisms in clinical trial design and analysis